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Rituximab therapy for refractory
systemic-onset juvenile idiopathic
arthritis
Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly
called Still’s disease, is a subset of juvenile arthritis that
describes patients with fever, rash, arthritis, serositis and
visceromegaly. In up to 30% of cases the disease has a chronic
course and management requires high doses of glucocorticoids,
disease-modifying antirheumatic drugs (DMARD), tumour
necrosis factor alpha (TNFa) inhibitors or anakinra.1–6
However, this therapeutic arsenal is unable to control the
disease in all patients.
Recently, rituximab, a chimeric anti-CD20 monoclonal
antibody, has been successfully used in two patients with
refractory adult-onset Still’s disease.7 As the similarity of
clinical and laboratory features present in SOJIA and adult-
onset Still’s disease implies that these conditions have similar
pathogenic mechanisms,1 2 we tested rituximab in three
patients with severe active SOJIA who had an inadequate
response or were intolerant to current treatment options. The
patients’ main characteristics at rituximab treatment initiation
and outcome data are summarised in table 1. In all cases the
disease persisted into adulthood, and at the time of the study
they presented with intermittent fever, rash, persistent
destructive polyarthritis and recurrent serositis (one patient).
They had all received at least four DMARD (range four to six),
intravenous immunoglobulin, one or more TNFa inhibitor and
anakinra, none of which proved to be successful.
Rituximab treatment consisted of two endovenous infusions
of 1 g per treatment cycle (except in one patient, who received
500 mg in the first cycle as a result of weighing only 40 kg),
separated by a 2-week interval (days 1 and 15). In one patient
rituximab was administered alone, whereas in the other two
cases it was given in combination with methotrexate. All
patients received premedication (100 mg methylprednisolone or
equivalent) to prevent infusion reactions.
The three patients showed a significant clinical improve-
ment, with remission of the systemic symptoms (fever, rash
and serositis). Arthritis improved partly in two cases, with re-
treatment being required 6–7 months later; in the other
patient, a low degree of activity was achieved and no further
treatment was required until 12 months later. Clinical
improvement was accompanied by a parallel improvement in
biological markers of inflammation, although in none of the
cases were the acute phase reactants normalised. The
concomitant oral steroid dose could be reduced to more than
half of the initial dose.
One of the patients presented with a severe hypersensitivity
reaction during the second infusion of the second treatment
cycle, but no other adverse effects were observed. None of the
Table 1 Patients’ main characteristics at rituximab treatment initiation and outcome data under therapy
Patient 1 Patient 2 Patient 3
Sex/age (years) F/29 F/30 F/29
Disease duration (years) 27 18 22
Previous treatments Anakinra, AZA, CsA,
ETA, GS, IG, MTX
Anakinra, CQ, ETA, GS,
IFX, LF, MTX
Anakinra, ADM, CsA,
DP, GS, IFX, IG, LF,
MTX, SSZ
Main symptoms at RTX treatment initiation Fever, rash, arthritis,
pleuritis, pericarditis
Fever, rash, arthritis Fever, rash, arthritis
ESR (mm/h)/CRP (mg/l) 75/171 104/258 64/128
TJC 28/SJC 28 9/5 25/24 11/6
DAS28 6.31 8.68 6.43
Dose of prednisone (mg/day) 30 10 30
Concomitant treatment associated with RTX MTX 15 mg/week MTX 15 mg/week None
Outcome
Response at month 6 Remission of systemic
symptoms
Remission of systemic
symptoms
Remission of systemic
symptoms
ESR 81/CRP 143 ESR 67/CRP 180 ESR 40/CRP 32
TJC 28 4/SJC 28 1 TJC 28 6/SJC 28 6 TJC 28 1/SJC 28 0
DAS28 4.62 DAS28 5.70 DAS28 3.28
Re-treatment: Yes Re-treatment: Yes Re-treatment: No
(severe hypersensitivity
reaction during 2nd
infusion)
Response at 1 year Remission of systemic
symptoms
Remission of systemic
symptoms
Remission of systemic
symptoms
ESR 53/CRP 94 ESR 65/CRP 141 ESR 44/CRP 47
TJC 28 5/SJC 28 2 TJC 28 7/SJC 28 5 TJC 28 3/SJC 28 2
DAS28 5.20 DAS28 5.59 DAS28 4.57
Re-treatment: Yes Re-treatment: Yes
Comments Prednisone daily
dosage reduced to
10 mg
Prednisone daily
dosage reduced to
5 mg
Prednisone daily
dosage reduced to
5 mg
ADM, adalimumab; AZA, azathioprine; CQ, chloroquine; CRP, C-reactive protein; CsA, ciclosporin A; DAS28, disease activity score in
28 joints; DP, D-penicillamine; ESR, erythrocyte sedimentation rate; ETA, etanercept; GS, gold salts; IG, intravenous polyvalent
immunoglobulin; IFX, infliximab; LF, leflunomide; MTX, methotrexate; RTX, rituximab; SJC, swollen joint count; SSZ, sulfasalazine;
TJC, tender joint count.
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patients suffered severe bacterial or opportunistic infections;
serum immunoglobulin levels remained within the normal
limits during treatment in all cases.
Our preliminary results suggest that rituximab seems to be a
useful therapeutic alternative in patients with active SOJIA in
whom previous treatments (including TNFa antagonists and
anakinra) have failed. Our experience is that rituximab
produces a substantial clinical improvement (remission of the
systemic symptoms and moderate European League Against
Rheumatism response of the arthritis), although the disease
does not enter into remission. Of interest, our experience with
rituximab is similar to the French experience with IL-1 receptor
antagonist treatment in SOJIA/adult-onset Still’s disease.6 In
that study, the benefits with anti-IL-1 therapy seem to be fair
in the systemic manifestations but reduced in the articular
complaints.
Further studies are needed to determine the place of specific
B-cell depletion in the treatment of refractory SOJIA.
J Narva´ez,1 C Dı´az-Torne´,2 X Juanola,1 C Geli,2 J M Llobet,2
J M Nolla,1 C Dı´az-Lo´pez2
1 Department of Rheumatology, Hospital Universitario de Bellvitge–IDIBELL, Barcelona,
Spain; 2 Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain
Correspondence to: Dr F J Narva´ez Garcı´a, Department of Rheumatology (planta
10–2), Hospital Universitario de Bellvitge, Feixa Llarga s/n 08907, L’Hospitalet de
Llobregat, Barcelona, Spain; 31577edd@comb.es
Competing interests: None.
Ethics approval: Ethics approval was obtained.
Patient consent: Obtained.
Accepted 26 July 2008
Ann Rheum Dis 2009;68:607–608. doi:10.1136/ard.2008.092106
REFERENCES
1. Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset
juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005;17:612–16.
2. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong
under juvenile idiopathic arthritis?. Rheumatology 2005;44:1350–3.
3. Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, et al. Anakinra treatment
for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology 2008;47:555–6.
4. Eberhard BA, Ilowite NT. Response of systemic onset juvenile rheumatoid arthritis to
etanercept: is the glass half full or hald empty?. J Rheumatol 2005;32:763–5.
5. Billiau AD, Cornillie F, Wouters C. Infliximab for systemic onset juvenile idiopathic
arthritis: experience in 3 children. J Rheumatol 2002;29:1111–14.
6. Lequerre´ T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1
receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile
idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann
Rheum Dis 2008;67:302–8.
7. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of
refractory adult onset Still’s disease with rituximab. Ann Rheum Dis 2006;65:1117–18.
The cover caption for the supplement published in December 2008 (volume 67, suppl iii) was
inadvertently missed from the contents page. It should have read ‘‘Part of ‘Augustine Roulin
with her infant’ by Vincent van Gogh (1889). Mrs Roulin suffered from psoriatic arthropathy.
Metropolitan Museum of Art, New York, USA.’’
Corrections
The authors JWJ Bijlsma and PMJ Welsing of the editorial ‘‘The art of medicine in treating
osteoarthritis: I will please’’ (Ann Rheum Dis 2008;67:1653–5) regret that a reference to an
important work by Dr Franklin G Miller (Department of Bioethics, National Institute of Health)
and co-workers was not included on p1654, first paragraph, right column. This part explains
findings reported in reference 12 and also text extracted from the following reference: Miller FG,
Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. J R Soc Med
2008;101:222–5. This reference should have been included together with reference 12.
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